The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Maintenance durvalumab after first-line platinum-based chemotherapy in advanced oesophago-gastric (OG) adenocarcinoma: Results from the PLATFORM trial.
 
Caroline Fong
No Relationships to Disclose
 
Bijal Patel
No Relationships to Disclose
 
Clare Peckitt
No Relationships to Disclose
 
Elli Bourmpaki
No Relationships to Disclose
 
Katharina von Loga
No Relationships to Disclose
 
Ruwaida Begum
No Relationships to Disclose
 
Michael Davidson
No Relationships to Disclose
 
Gayathri Anandappa
No Relationships to Disclose
 
Catherine Cafferkey
No Relationships to Disclose
 
David J. Watkins
No Relationships to Disclose
 
Sheela Rao
Consulting or Advisory Role - Bayer; Roche
Travel, Accommodations, Expenses - Bayer; Incyte
 
Tom Waddell
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Merck Sharp & Dohme; Pfizer; Roche
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EUSA Pharma; Ipsen
 
Jonathan Wadsley
Consulting or Advisory Role - AstraZeneca; Eisai; Genzyme; Ipsen; Lilly; Novartis; Roche
Speakers' Bureau - Eisai; Lilly; Novartis
Research Funding - AstraZeneca; Genzyme
Travel, Accommodations, Expenses - Novartis
 
Fareeda Coxon
No Relationships to Disclose
 
Tom Roques
No Relationships to Disclose
 
Carys Morgan
No Relationships to Disclose
 
Charlotte Rees
Travel, Accommodations, Expenses - Amgen
 
Naureen Starling
Honoraria - Amgen; GlaxoSmithKline; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; SERVIER
Consulting or Advisory Role - AstraZeneca; MSD; Pfizer; SERVIER
Research Funding - AstraZeneca (Inst); BMS (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; Lilly; Merck; MSD Oncology; Roche
 
Ian Chau
Honoraria - Lilly
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Incyte; Lilly; Merck Serono; MSD Oncology; OncXerna Therapeutics; Pierre Fabre; Roche/Genentech
Research Funding - Janssen-Cilag (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck Serono; MSD
 
David Cunningham
Stock and Other Ownership Interests - OVIBIO
Consulting or Advisory Role - OVIBIO
Research Funding - 4SC (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Clovis Oncology (Inst); Leap Oncology (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Roche (Inst)